Establishment Labs’ (ESTA) “Overweight” Rating Reiterated at Stephens

Establishment Labs (NASDAQ:ESTA)‘s stock had its “overweight” rating reissued by equities researchers at Stephens in a report released on Thursday,Benzinga reports. They currently have a $52.00 price objective on the stock. Stephens’ target price points to a potential upside of 23.96% from the company’s previous close.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA opened at $41.95 on Thursday. The business’s 50 day moving average price is $37.53 and its 200-day moving average price is $41.38. The firm has a market capitalization of $1.21 billion, a PE ratio of -16.26 and a beta of 0.95. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. Establishment Labs has a 1 year low of $28.16 and a 1 year high of $60.12.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to analyst estimates of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. As a group, equities research analysts expect that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Establishment Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ESTA. Barclays PLC raised its position in Establishment Labs by 9,643.3% in the third quarter. Barclays PLC now owns 31,471 shares of the company’s stock valued at $1,362,000 after purchasing an additional 31,148 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Establishment Labs by 89.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,351 shares of the company’s stock valued at $1,789,000 after purchasing an additional 19,531 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Establishment Labs in the fourth quarter valued at $12,898,000. Vestal Point Capital LP purchased a new stake in Establishment Labs in the third quarter valued at $1,731,000. Finally, Point72 Asset Management L.P. raised its position in Establishment Labs by 210.8% in the third quarter. Point72 Asset Management L.P. now owns 49,400 shares of the company’s stock valued at $2,138,000 after purchasing an additional 33,507 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.